Clinical and Translational Oncology

, Volume 19, Issue 12, pp 1430–1437 | Cite as

Biomarkers in pancreatic ductal adenocarcinoma

  • J. Gallego
  • C. López
  • R. Pazo-Cid
  • F. López-Ríos
  • A. Carrato
Review article
First Online:
Received:
Accepted:

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease. Nomenclature for molecular subtypes of tumours is gradually gaining acceptance and there are growing expectations it will further go from the bench to the bedside. However, the clinical relevance of biomarkers in PDAC is still far behind the relevance of biomarkers in other solid tumours. This article is part of a wider project (GALLgo) involving over forty specialists devoted to the multidisciplinary management of PDAC which concluded in recommendations based on scientific evidence. The aim of the present article is to review the diagnostic, prognostic and predictive biomarkers, either in localised or advanced disease, which have been lately subjected to study and analysis and others currently available for PDAC in order to give strength-graded recommendations linked to quality of evidence that can be used as guidelines in routine clinical practice.

Keywords

Pancreatic ductal adenocarcinoma Prognostic Predictive Dynamic Biomarkers 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

The authors thank Sofía Perea, Pharm D, Ph.D, for her support in writing the manuscript. The support for medical writing was supported by Fundación ECO.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

For this type of study formal consent is not required.

References

  1. 1.
    GLOBOCAN. European age-standardised rates calculated by the statistical information team at cancer research UK, 2011 using data from GLOBOCAN 2008 v1.2, IARC, version 1.2. http://globocan.iarc.fr. Accessed Feb 2016.
  2. 2.
    Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139–44.CrossRefPubMedGoogle Scholar
  3. 3.
    Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33:244–50.Google Scholar
  4. 4.
    Holter S, Borgida A, Dodd A, Grant R, Semotiuk K, Hedley D, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015;33:3124–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KD, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495–501.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42:8–18.CrossRefPubMedGoogle Scholar
  7. 7.
    Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;S5:v56–68.Google Scholar
  8. 8.
    Yi JM, Guzzetta AA, Bailey VJ, Downing SR, Van Neste L, Chiappinelli KB, et al. Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res. 2013;19:6544–55.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ferrone CR, Kattan MW, Tomlinson JS, Thayer SP, Brennan MF, Warshaw AL, et al. Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol. 2005;23:7529–35.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Uzunoglu FG, Reeh M, Vetorazzi E, Ruschke T, Hannah P, Nentwich MF, et al. Preoperative Pancreatic Resection (PREPARE) score. A prospective multicenter-based morbidity risk score. Ann Surg. 2014;260:857–64.CrossRefPubMedGoogle Scholar
  11. 11.
    Humphris JL, Chang DK, Johns AL, Scarlett CJ, Paijic M, Jones MD, et al. Prognostic and predictive value of serum CA 19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713–22.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Yang JJ, Hu CG, Shi WX, Denq T, He SQ, Yuan SG, et al. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World J Gastroeterol. 2015;21:2807–15.CrossRefGoogle Scholar
  13. 13.
    Bachet JB, Maréchal R, Demetter P, Bonnetain F, Couvelard A, Syrcek M, et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Ann Oncol. 2012;23:2327–35.CrossRefPubMedGoogle Scholar
  14. 14.
    Kim H, Park CY, Lee JH, Cho CK, Kim KH. Ki-67 and p53 expression as a predictive marker for early postoperative recurrence in pancreatic head cancer. Ann Surg Treat Res. 2013;88:200–7.CrossRefGoogle Scholar
  15. 15.
    Xie H, Jiang W, Xiao SY, Liu X. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma. J Histochem Cytochem. 2013;61:148–55.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Maréchal R, Bachet JB, Calomme A, Demetter P, Delpero JR, Syrcek M, et al. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma. Clin Cancer Res. 2015;21:1215–24.CrossRefPubMedGoogle Scholar
  17. 17.
    Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, et al. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 2010;7:e1000307.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hamada T, Nakai Y, Yasunaga H, Isayama H, Matsui H, Takahara N, et al. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Br J Cancer. 2014;110:1943–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRefGoogle Scholar
  21. 21.
    Tabernero J, Chiorean G, Infante JR, Hingorani SR, Ganjue V, Weeks C, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist. 2015;20:1–8.CrossRefGoogle Scholar
  22. 22.
    Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouam Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMedGoogle Scholar
  23. 23.
    Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer. 2013;119:285–92.CrossRefPubMedGoogle Scholar
  24. 24.
    Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107:1–10.Google Scholar
  25. 25.
    Qi Q, Geng Y, Sun M, Wang P, Chen Z. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer. Pancreatology. 2015;15:145–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Lamarca A, Feliu J. Pancreatic biomarkers: could they be the answer? World J Gastroenterol. 2014;20:7819–29.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, et al. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. J Natl Cancer Inst. 2015;107:1–9.CrossRefGoogle Scholar
  28. 28.
    Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2011;10:3–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500–3.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47:1168–78.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Combs SE, Habermehl D, Kessel KA, Bergmann F, Werner J, Naumann P, et al. Prognostic impact of CA 19.9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer. Ann Surg Oncol. 2014;21:2801–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Lee JW, Kang CM, Choi HJ, Lee WJ, Song SY, Lee H, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with pancreatic cancer. J Nucl Med. 2014;55:898–904.CrossRefPubMedGoogle Scholar
  33. 33.
    Haas M, Heinemann V, Kullmann F, Laubender RP, Klose C, Bruns CJ, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139:681–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Aranda E, Manzano JL, Rivera F, Galán M, Valladares-Ayerbes M, Pericay C, et al. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). Ann Oncol. 2012;23:1919–25.CrossRefPubMedGoogle Scholar
  35. 35.
    Ramanathan RK, Von Hoff DD, Moore MJ, Texeira L, Salvatore S, Tabernero J, et al. Analysis of metabolic response by positron emission tomography compared with tumor response by computed tomography from MPACT, a phase III trial comparing nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2014;32:254 (abstr).CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Authors and Affiliations

  1. 1.Department of Medical OncologyUniversity Hospital of ElcheAlicanteSpain
  2. 2.Department of Medical OncologyHospital Universitario Marqués de ValdecillaSantanderSpain
  3. 3.Department of Medical OncologyHospital Universitario Miguel ServetSaragossaSpain
  4. 4.Department of Pathology, Laboratorio de Dianas TerapéuticasHospital Universitario HM SanchinarroMadridSpain
  5. 5.Department of Medical OncologyMadridSpain

Personalised recommendations